Interview Intersection: Expert Interviews From February 2026

Clinical Updates

Del Rosso's What's New in the Medicine Chest 2026: Mastocytosis and Inflammatory Disease

James Del Rosso, DO, discusses diagnosis and treatment of mastocytosis and inflammatory conditions.

MORE FROM DEL ROSSO: Evolving Treatment Strategies with James Del Rosso, DO

South Beach Symposium 2026: Gold's Top Pearls

Michael Gold, MD, shares insights on safer device use, peptides, GLP-1s, acne, hair therapies, and more.

Chronic SD Requires Mechanism-Based Management

At South Beach Symposium 2026, Benjamin Ungar, MD, discussed safer, long-term approaches for seborrheic dermatitis.

Mona Shahriari, MD, FAAD, on OX40-Targeted Therapy in AD

At South Beach Symposium 2026, Mona Shahriari explores OX40/OX40L therapies for atopic dermatitis.

Victoria Werth, MD, Discusses the Future of BDCA2 Inhibition in Cutaneous Lupus

Victoria Werth, MD, highlights CLE treatment gaps and how BDCA2-targeting litifilimab may quickly curb interferon-driven skin disease with less toxicity.

MORE INSIGHTS FROM WERTH: From LILAC to AMETHYST: The Rapid Efficacy of Litifilimab in CLE

Unique Perspectives

MOPD 2026 Rookie of the Year: Integrating Endocrine Insight Into Adolescent Acne Care

At MOPD 2026, Kristina Derrick, MD, ScM, links teen acne to hormones and metabolism, highlighting PCOS clues and antiandrogen therapies.

When Innovation Meets Insurance Barriers With Lisa Swanson, MD

Clinicians are increasingly facing barriers when attempting to prescribe on-label treatments for indicated patients.

Targeting Sebum at the Source: Neal Bhatia, MD, on the Promise of Denifanstat

Neal Bhatia, MD, explores denifanstat for acne—oral FASN inhibition that curbs sebum, boosts outcomes, and may be an alternative to antibiotics or retinoids.

The Path to Long-Term Control: Thrasyvoulos Tzellos, MD, PhD, Discusses the Burden of HS

Thrasyvoulos Tzellos, MD, PhD, explains HS’s progressive toll and how UCB’s BE HEARD bimekizumab data shows durable tunnel reduction and lasting disease improvement.

MORE FROM TZELLOS: The Clinical Impact of IL-17 Blockade in Hidradenitis Suppurativa Draining Tunnels

Systemic Mastocytosis Advocate Shares Diagnostic Delays, Multisystem Burden, and the Impact of Targeted Therapy

Patient advocate Suki Tipp details her progression from misattributed cutaneous findings and fragmented specialty care to life-threatening anaphylaxis and eventual disease control with targeted therapy.

Breaking Barriers in Aesthetics: Joni Jefferson, DO on Representation, Patient Education, and the Power of Mentorship

Joni Jefferson, DO, spotlights skin of color dermatology, safer lasers, mentorship, and the future of aesthetic medicine during Black History Month.

Conference Insights

Kicking Off MOPD 2026 With Lawrence Schachner, MD

MOPD 2026 brings together leading experts to review recent therapeutic advances and practical management strategies in pediatric dermatology.

Rethinking Menopause-Related Skin Changes in Clinical Practice

Glynis Ablon, MD, FAAD, examines the intersection of menopause, hormones, and dermatologic health.

South Beach Symposium 2026 Showcases Advances in Medical and Aesthetic Dermatology

The 2026 meeting emphasized integrating cutting-edge medical therapies with aesthetic strategies to address both disease control and quality of life.

MORE FROM BUNICK: Christopher Bunick, MD, PhD, on Expanding Targets in Inflammatory Skin Disease

Best Practices

Expanding Nonsurgical Options for Superficial BCC With Red Light PDT

Todd Schlesinger, MD, discusses emerging evidence, clearance outcomes, and practical considerations for using red light–based photodynamic therapy as a nonsurgical option in select superficial basal cell carcinoma (BCC) cases.

MORE FROM SCHLESINGER: Red Light Photodynamic Therapy Sets Evidence-Based Standard for sBCC, Photodynamic Therapy for sBCC Shows Predictable Clearance and High In-Office Adherence

Ablon's Alopecia and Aesthetic Best Practices

Glynis Ablon, MD, FAAD, shares insights on diagnosing alopecia fast, managing aesthetic complications, and choosing evidence-based supplements.

Misha Rosenbach, MD, on the Clinical and Psychosocial Burden of Cutaneous Sarcoidosis

Misha Rosenbach, MD, discussed the burden of cutaneous sarcoidosis (CS) and how emerging therapies like brepocitinib could fill this clinical need.

MORE FROM ROSENBACH: Brepocitinib’s Unprecedented Phase 2 Results in Neglected and Rare Cutaneous Disease

Getting Melanoma Right From the First Biopsy

At the 2026 South Beach Symposium, Joel Claveau, MD, emphasized that accurate early diagnosis and proper staging are the cornerstones of effective melanoma management.

Reflections and Looking Ahead

Less Is More: A Practical Approach to Tween Skin Care

At MOPD 2026, Lisa Swanson, MD, urges fungal cultures amid terbinafine resistance and warns attendees about risky kids’ skin care trends.

Transparency and Trust in Off-Label Prescribing

Highlighting conditions like lichen planus, which has no FDA-approved treatments, Lio underscores why clinicians must be comfortable prescribing beyond the label.

A Team-Based Model for Efficient PDT Delivery

Michael O’Donoghue, MD, outlines how delegating PDT workflows to trained medical assistants can preserve physician time while maintaining treatment quality.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.